Back to top
more

ContraVir Pharmaceuticals Inc (HEPA)

(Real Time Quote from BATS)

$1.81 USD

1.81
115,023

-0.06 (-3.21%)

Updated May 29, 2020 02:02 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
23.52%
17.07%
8.72%
4.30%
1.24%
10.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | A Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data

It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.

SNY REGN EPZM GILD XLRN INCY HEPA

Zacks Equity Research

Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII

Zacks.com featured highlights include: JBGS, NWBI, THG, HEPA and HSII

NWBI THG HSII JBGS HEPA

Shrabana Mukherjee

5 Stocks in Focus as Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

NWBI THG HSII JBGS HEPA

Zacks Equity Research

Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF

Zacks.com featured highlights include: NWBI, THG, RUBI, HEPA and KOF

RUBI KOF NWBI THG HEPA

Shrabana Mukherjee

Buy These 5 Stocks as New Analysts Initiate Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

RUBI KOF NWBI THG HEPA

Sweta Killa

Healthcare ETFs Win in October: Here's Why

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

PFE MRK IHF XBI SBIO BBC XPH BIIB ALXN HEPA GNOM

Sweta Killa

Biotech ETFs Surge on a Flurry of Positive News

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

XBI BTEC BBC BBP SBIO SPY BIIB ALXN HEPA IDNA